CAPTOR THHERAP. ZY-10

Research CAPTOR THHERAP. ZY-10 (60Q) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 4.66M-EUR 42.00M-EUR 37.53M69.0%n/aEUR 10.72MEUR 3.58MEUR 23.48M
FY2022PLN 9.16M-PLN 35.89Mn/a77.2%-8240PLN 71.04Mn/aPLN 96.32M
FY2021PLN 3.99M-PLN 32.57Mn/a81.4%-7480PLN 117.94Mn/aPLN 124.20M

About CAPTOR THHERAP. ZY-10

General Information 1. The information on the Capital Group Captor Therapeutics S.A. (the "Company", "Entity", "Dominant Entity", or "Issuer") was entered into the Polish National Court Register on December 30, 2015, as a limited liability company under number KRS 0000594615, and subsequently transformed into an SA. The transformation of Captor Therapeutics Sp. z o.o. into Captor Therapeutics S.A.

Related stock research

Other related stocks

Frequently asked questions

What does CAPTOR THHERAP. ZY-10 do?

General Information 1. The information on the Capital Group Captor Therapeutics S.A. (the "Company", "Entity", "Dominant Entity", or "Issuer") was entered into the Polish National Court Register on December 30, 2015, as a limited liability company under number KRS 0000594615, and subsequently transformed into an SA. The transformation of Captor Therapeutics Sp. z o.o. into Captor Therapeutics S.A. was carried out in accordance with Article 551 of the Commercial Companies Code, based on a resolution of the Extraordinary General Meeting of Shareholders of Captor Therapeutics Sp. z o.o.